Organic compounds as agents for the treatment of aldosterone mediated conditions

Abstract From the Canadian patent

Compounds of formula (I), provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase and thus may be employed for the , treatment of aldosterone mediated conditions. Accordingly the compounds of , formula (I) may be employed for prevention delay of progression, or treatment , of hypokalemia hypertension, congestive heart failure renal failure, in , particular, chronic renal failure restenosis, atherosclerosis, syndrome X obesity, nephropathy, post myocardial infarction coronary heart diseases, increased formation of collagen fibrosis, and remodeling following , hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are …